Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-02-22
2011-11-01
Aeder, Sean (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
08048992
ABSTRACT:
It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.
REFERENCES:
patent: WO-01/062907 (2001-08-01), None
patent: WO-01/096401 (2001-12-01), None
patent: WO 02/14557 (2002-02-01), None
patent: WO-2005/012530 (2005-02-01), None
Yageta et al (Cancer Research, 2002, 62(18): 5129-5133).
Ito et al (Cancer Research, 2001, 63: 6320-6326).
Mountain et al (Biotechnol, Genet Eng Rev, 1992, 10: Abstract).
Gilbert Laurent et al., “Nectin-like Protein 2 Defines a Subset of T-cell Zone Dendritic Cells and Is a Ligand for Class-I-restricted T-cell-associated Molecule,” The journal of biological chemistry, vol. 280, No. 23, 2005, pp. 21955-21964 (Epub. Mar. 21, 2005).
Tetsuo Ito et al., “Involvement of TSLC1 in Progression of Esophageal Squamous Cell Carcinoma,” Cancer Research, vol. 63, No. 19, Oct. 1, 2003, pp. 6320-6326.
Hidenori Sasaki et al., “Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia,” BLOOD, Cancer Research, vol. 105, No. 3, Feb. 1, 2005, pp. 1204-1213 (Epub. Oct. 7, 2004).
Suzanne A. Eccles, “Monoclonal antibodies targeting cancer: ‘Magic bullets’ or just the trigger?,” Breast Cancer Research, 2001, vol. 3, No. 2, pp. 86-90 (Epub. Dec. 20, 2000).
L. G. Presta et al., “Engineering therapeutic antibodies for improved function,” Biochemical Society Transactions, 2002, vol. 30, No. 4, pp. 487-490.
Raymond J. Owens et al., “The genetic engineering of monoclonal antibodies,” Journal of Immunological Methods, 1994, vol. 168, No. 2, pp. 149-165.
Greg Winter et al., “Humanized antibodies,” Immunology Today, 1993, vol. 14, No. 6, pp. 243-246.
Greg Winter et al., “Antibody-based therapy,” Trends in pharmacologicalsciences, vol. 14, No. 5, May 1993, pp. 139-143.
Mass R et al., Proc Am Soci Clin Oncol , vol. 19, 2000, 75a (1 page).
N. L. Berinstein et al.. “Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma,” Annals of Oncology 9, 1998, pp. 995-1001.
Marianne Brüggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies,” Neuberger M. S., J.E. xp. Med., vol. 166, Nov. 1987, pp. 1351-1361.
Michael Loos, “The Classical Complement Pathway: Mechanism of Activation of the First Component by Antigen-Antibody Complexes,” Prog. Allergy, vol. 30, 1982, pp. 135-192.
Jürg Tschopp, “Kinetics of Activation of the First Component of Complement (C1) by IgG Oligomers,” Mol Immunol., vol. 19, No. 5, May 1982, pp. 651-657.
T. Wakayama et al., “Express on and Funct onal Character zat on of the Adhes on Molecule Spermatogen c Immunoglobul n Superfam ly n the Mouse Test s, ”Biology of Reproduction, vol. 68, No. 5, XP-002517587, May 2003, pp. 1755-1763.
T. Ito et al., “Involvement of TSLC1 in Progression of Esophageal Squamous Cell Carcinoma,” Cancer Research, XP003000773, Oct. 1, 2003, pp. 6320-6326.
Supplementary European Search Report dated Mar. 17, 2009, issued on the European application No. 06714335.4.
Toyohide Shinkawa et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity,” The Journal of Biological Chemistry, vol. 278, No. 5, 2003, pp. 3466-3473.
Akahori Yasushi
Azuma Masachika
Fujiyama Sari
Hayashi Nobuhiro
Iba Yoshitaka
Aeder Sean
Edwards Angell Palmer & & Dodge LLP
Institute for Antibodies Co., Ltd.
Kurosawa Yoshikazu
LandOfFree
Anti-IgSF4 antibody and utilization of the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IgSF4 antibody and utilization of the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IgSF4 antibody and utilization of the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4306635